VIDEO: Subcutaneous ocrelizumab offers similar safety, efficacy to IV administration in MS

DENVER — Subcutaneous administration of ocrelizumab showed similar safety and efficacy profiles to IV administration in multiple sclerosis at 24 weeks, according to David Jones, senior medical director at Genentech.

Jones discussed the OCARINA 2 clinical trial in this Healio video from the American Academy of Neurology annual meeting.

In the ongoing phase 3 OCARINA 2 trial, 236 individuals with relapsing or primary progressive MS were randomized to receive either 920 mg subcutaneous ocrelizumab (Ocrevus, Genentech) or 600 mg IV ocrelizumab over 48 weeks.

According to interim results, at week 24, treatment with subcutaneous formulation led to near-complete suppression of relapse in a similar manner to IV administration. In addition, subcutaneous administration demonstrated a similar safety and tolerability profile to IV administration.

Patient-reported outcome data derived from the 13-question Treatment Administration Satisfaction Questionnaire for subcutaneous medicine also yielded positive results.

“Patients were satisfied with the procedure,” Jones told Healio. “They thought the time the procedure took was just right and they would recommend it.”